Skip to main content
. 2016 Jan 1;37(4):1527–1539. doi: 10.1177/0271678X16658301

Figure 2.

Figure 2.

Impact of ACVD and MMD patients' serum on vessel-destabilizing factors in cENDs. (a) Scheme illustrating the protocol used for cEND cell treatment with patients’ serum followed by experimental analysis. (b) Relative gene expression of ang-2, ang-1, and tie-2 was assessed in the presence of ACVD versus MMD serum for 24 hours by qPCR. (c) Protein expression of Ang-2 and Ang-1 normalized to the expression of β-actin in response to MMD versus ACVD serum tested by Western blot. Images were chosen from a representative experiment. The respective densitometrical analysis was displayed in the graph. (d) Extracellular secretion of angiopoietin-2 in response to patients serum monitored in cENDs using ELISA. Values in the graphs are means ± SEM, (n = 3 independent experiments each including at least six different patients’ sera of each clinical type) ****p < 0.001, ***p < 0.001, **p < 0.01, *p < 0.05 versus ACVD-incubated cENDs.